Healthcare Private Placement and M&A Transactions Review Week Ending January 18, 2026

Inquis Medical: The company raised $75 million of Series C venture funding from undisclosed investors on January 12, 2026, putting the company’s pre-money valuation at $300 million. The company is a developer of a peripheral thrombectomy medical device designed for treating pulmonary embolism and deep vein thrombosis.

Cytotheryx: The company raised $60 million of Series A venture funding led by Ouroboros Group on January 12, 2026. The company is a developer of a therapeutic platform designed to develop cell-based therapies for acute, chronic, and rare liver diseases.

VieCure: The company raised $43 million of venture funding in a deal led by Northpond Ventures and Mitchell Rales on January 12, 2026. Socium Ventures, Sator Grove Holdings and Durable Capital Partners also participated in the round. The company is a developer of an AI-powered comprehensive cancer care platform for personalized oncology treatment planning.

Trailhead Biosystems: The company raised $40 million of venture funding in a deal led by MAK Capital on January 12, 2026. The company is a developer of biotechnology drugs and cell therapies for advanced therapeutic production.

Caldera Therapeutics: The company raised $37.5 million of Series A venture funding from Omega Funds, Wellington Management and Janus Henderson Investors on January 14, 2026. The company is a developer of bispecific antibody therapeutics for inflammatory bowel disease treatment.

Juvena Therapeutics: The company raised $33.5 million of Series B venture funding in a deal led by Bison Ventures on January 12, 2026. Eli Lilly, Jefferson Life Sciences, Manta Ray Ventures, Mubadala Investment Company and other undisclosed investors also participated in the round. The company is a developer of a biopharmaceutical drug discovery platform intended to discover novel protein-based therapeutics.

Vista.ai: The company raised $29.5 million of Series B venture funding from Intermountain Healthcare, Tampa General Hospital and Cedars Sinai Health Ventures on January 14, 2026, putting the company’s pre-money valuation at $446.5 million. Khosla Ventures, Bold Brain Capital, University of Utah Health, Temple University, and other undisclosed investors also participated in the round. The company is a developer of a diagnostic imaging technology designed to aid in the treatment of cardiovascular diseases.

Converge Bio: The company raised $25 million of Series A venture funding in a deal led by Bessemer Venture Partners on January 13, 2026, putting the company’s pre-money valuation at $65 million. TLV Partners, Vintage (Private Equity), and other undisclosed investors also participated in the round. The company is a developer of a biotech platform designed to integrate generative artificial intelligence with biological data to accelerate drug discovery and development.

PrognomIQ: The company raised $21.9 million of venture funding from undisclosed investors on January 16, 2026. The company is a developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases.

Recludix Pharma: The company raised an estimated $21.5 million of Series B venture funding from Access Biotechnology, Eli Lilly and Westlake Village BioPartners on January 12, 2026, putting the company’s pre-money valuation at $315.5 million. New Enterprise Associates, Alexandria Venture Investments, and other undisclosed investors also participated in the round. The company is an operator of a drug discovery business intended to treat cancer and autoimmune diseases.

Shorla Oncology: The company raised EUR 18 million of venture funding from Enterprise Ireland and other undisclosed investors on January 17, 2026. The company is a developer of reformulated oncology medicines improving existing cancer treatments through alternative delivery formulations.

Cardamom Health: The company raised an estimated $15 million of Series A venture funding from Valspring Capital and other undisclosed investors on January 12, 2026, putting the company’s pre-money valuation at $83 million. The company is a provider of electronic health record consulting services for healthcare IT infrastructure optimization.

MedWatch Technologies: The company raised $15 million of Series A venture funding in a deal led by Stead Impact Ventures and Foundation on January 16, 2026. The company is a developer of a non-invasive glucose monitoring watch and accompanying health management platform designed for people suffering from diabetes.

Risa Labs: The company raised $11.1 million of Series A venture funding in a deal led by Cencora Ventures and Optum Ventures on January 12, 2026, putting the company’s pre-money valuation at $30.9 million. Oncology Ventures, z21 Ventures, Binny Bansal, John Simon and other undisclosed investors also participated in the round. The company is a developer of an AI-driven multi-agent system platform for medical necessity determination in prior authorization workflows.

Vivere Oncotherapies: The company raised $10 million of venture funding from Pillar VC, Berkeley Frontier Fund and Freeflow Ventures on January 13, 2026. YK Bioventures and National Cancer Institute also participated in the round. The company is a developer of gene therapy delivery technology for immunotherapy in cold solid tumors.

Nanochon: The company raised $4.1 million of venture funding in a deal led by Cultivate(MD) on January 12, 2026. Wilson Sonsini Goodrich & Rosati, Wealthing VC Club, Wealthing VC Fund, University of Virginia and other undisclosed investors also participated in the round. The company is a developer of a 3D-printed cartilage implant designed to replace damaged cartilage and promote new tissue growth.

Applied Brain Research: The company raised $3.6 million of venture funding in a deal led by Two Small Fish Ventures on January 12, 2026. The company is a developer of state space network technology for neuromorphic AI on edge devices.

Avalon Healthcare Solutions: The company received an undisclosed amount of development capital from Francisco Partners and WindRose Health Investors on January 12, 2026. The company is a developer of a laboratory benefit management platform for diagnostic testing authorization and utilization management.

Basecamp Research: The company raised an undisclosed amount of venture funding from nVentures on January 12, 2026. The company is a developer of a biological design platform exploring natural biodiversity for protein engineering.

Distalmotion: The company raised an undisclosed amount of venture funding from Johnson & Johnson JJDC on January 12, 2026. The company is a developer of surgical robotic technology for minimally invasive procedures.

Innovative Molecules: The company is in the process of raising venture funding from Alfasigma on January 14, 2026. The company is a developer of therapeutics for herpes simplex virus-induced diseases.

PulseAI: The company raised an undisclosed amount of venture funding in a deal led by Innovation Ulster on January 12, 2026. Mortara Group and The Francis Crick Institute also participated in the round. The company is a developer of an artificial intelligence-powered heart screening software designed to improve the accuracy, efficiency, and scalability of cardiac diagnostics.

Syd life AI: The company raised Series A venture funding from Shizen Capital and other undisclosed investors on January 15, 2026, putting the company’s pre-money valuation at GBP 316 million. The company is a developer of predictive analytics services for governments, insurers, healthcare, and pharmaceutical industries.

Penumbra / Boston Scientific: The company reached a definitive agreement to be acquired by Boston Scientific for an estimated $15 billion on January 15, 2026. The company is a manufacturer of thrombectomy and embolization devices for mechanical blood clot removal.

Oxb / EQT: The company has received bids to be acquired by EQT through an estimated GBP 900 million public-to-private LBO as of January 14, 2026. The company is a contract development and manufacturing organization for cell and gene therapy.

Integrity Orthopaedics / Smith & Nephew: The company reached a definitive agreement to be acquired by Smith & Nephew, for $450 million on January 12, 2026. The company is a developer of rotator cuff repair devices for soft tissue repair.

Torch / OpenAI: The company was acquired by OpenAI for an estimated $100 million on January 12, 2026. The company is a developer of a personal health data management application for patients and healthcare consumers.

Arete Wellness / Agentis Longevity: The company was acquired by Agentis Longevity, via its financial sponsor Shore Capital Partners, through an LBO on January 13, 2026 for an undisclosed amount. The company is a provider of personalized health and performance treatments such as IV therapy, cryotherapy, and hyperbaric oxygen therapy.

CombinAble.AI / insitro: The company reached a definitive agreement to be acquired by insitro for an undisclosed amount on January 12, 2026. The company is a developer of an AI-driven antibody development platform for optimizing therapeutic antibodies.

Grove AI / Hippocratic AI: The company was acquired by Hippocratic AI for an undisclosed amount on January 12, 2026. The company is a developer of a clinical trial management platform intended to enhance participant engagement and streamline trial processes.

Keet Health / ACE & Company: The company was acquired by Net Health Systems, via its financial sponsors The Carlyle Group, Silversmith Capital Partners, Level Equity and ACE & Company, through an LBO on January 13, 2026 for an undisclosed amount. The company is a developer of a patient engagement platform for improving clinical experience.

Modella AI / AstraZeneca: The company was acquired by AstraZeneca for an undisclosed amount on January 13, 2026. The company is a developer of advanced artificial intelligence tools designed to revolutionize diagnostic, prognostic, and therapeutic workflows in healthcare.

NeuroNOS / Xtl Biopharmaceuticals: The company reached a definitive agreement to be acquired by Xtl Biopharmaceuticals for an undisclosed amount on January 13, 2026. The company is an operator of a biopharmaceutical business intended to treat autism spectrum disorder.

Oncompass Medicine / Genomate Health: The company was acquired by Genomate Health for an undisclosed amount on January 14, 2026. The company is a provider of precision oncology and cancer therapy information services.

Orchid Orthopedic Solutions / Tecomet: The company was acquired by Tecomet, via its financial sponsors Athyrium Capital Management, Charlesbank Capital Partners, Bain Capital Credit, and Crescent Capital Group, through an LBO on January 14, 2025 for an undisclosed amount. The company is a manufacturer of orthopedic implants for joint replacement and trauma markets.

PathoQuest / Charles River Laboratories International: The company reached a definitive agreement to be acquired by Charles River Laboratories International for an undisclosed amount on January 12, 2026. The company is a developer of a molecular diagnostics technology designed to improve pathogen detection in biological samples.

Proveris Scientific / Investindustrial: The company was acquired by Investindustrial and Mr. Dino J. Farina through an LBO on January 13, 2026 for an undisclosed amount. The company is a provider of pharmaceutical device development and testing services for orally inhaled and nasal drug products.

Rivet Health / Zelis Healthcare: The company was acquired by Zelis Healthcare, via its financial sponsors Bain Capital, Parthenon Capital Partners, Valspring Capital, BPEA Private Equity, Edison Partners, Bain Capital Ventures, Norwest, Ergo Partners, HarbourVest Partners, and Mubadala Investment Company, through an LBO on January 12, 2026 for an undisclosed amount. The company is a developer of a revenue cycle management platform for payer contract optimization and claim denial prevention.

ROME Therapeutics / Pretzel Therapeutics: The company was acquired by Pretzel Therapeutics for an undisclosed amount on January 12, 2026. The company is a developer of novel therapies intended to cure cancer and autoimmune diseases.

Sensable Health / MedWatch Technologies: The company was acquired by MedWatch Technologies for an undisclosed amount on January 14, 2026. The company is a developer of a health and wellness application for personalized weight loss programs.

SpineHawk / VB Spine: The company entered into a definitive agreement to be acquired by VB Spine, via its financial sponsor Viscogliosi Bros, through an LBO on January 15, 2026 for an undisclosed amount. The company is a developer of a surgical robotics and visualization platform for spine and neuroendoscopic procedures.

TerSera Therapeutics / Esteve Healthcare: Esteve Healthcare reached a definitive agreement to acquire the infusion specialty therapies business unit of Tersera Therapeutics for an undisclosed amount on January 13, 2026. The company is a developer of Prialt and Quzyttir infusion specialty medicines.

Valencia Technologies / Boston Scientific: The company reached a definitive agreement to be acquired by Boston Scientific for an undisclosed amount on January 12, 2026. The company is a developer of miniaturized fully-implanted neurostimulators for peripheral nerve stimulation treating chronic conditions.